REG - Arecor Therapeutics - Change of Nominated Advisor and Joint Broker

Arecor TherapeuticsAnnouncement

09/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250109:nRSI6601Sa&default-theme=true

RNS Number : 6601S  Arecor Therapeutics PLC  09 January 2025

Arecor Therapeutics plc

("Arecor" or the "Group")

 

CHANGE OF NOMINATED ADVISOR AND JOINT BROKER

 

Cambridge, UK, 9 January 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that Singer Capital Markets Advisory LLP has been appointed as
the Company's Nominated Advisor and Joint Broker with immediate effect.

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                       www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                      Tel: +44 (0) 1223 426060

 David Ellam, Interim Chief Financial Officer                  Email: info@arecor.com (mailto:info@arecor.com)
 Singer Capital Markets Advisory LLP (NOMAD and Joint Broker)

 Phil Davies, Sam Butcher                                      Tel : +44 (0) 20 7496 3000

 WG Partners LLP (Joint Broker)
 Nigel Barnes, Satheesh Nadarajah                              Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville                   Tel: +44 (0) 20 3709 5700

                                                               Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPSSLESAEISEEF